Tislelizumab Combined With Chemotherapy
Phase 3Small molecule
Tislelizumab Combined With Chemotherapy is one of 115 small molecule programs targeting Non Small Cell Lung Cancer Metastatic. It is currently in Phase 3.
4
Indications
4
Total Trials
4
Active Trials
114
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
449 competitors in Non-Small Cell Lung Cancer
#DrugCompanyPhaseTrials
1Furmonertinib
AAllist Pharmaceuticals, Inc.
Phase 3
Tislelizumab Combined With Chemotherapy
FFirst Affiliated Hospital of Guangxi Medical University
Phase 3
Anamorelin Hydrochloride
MM.D. Anderson Cancer Center
Phase 3
Pemetrexed or Nab-Paclitaxel
SShanghai Pulmonary Hospital, Shanghai, China
Phase 3
Remeron
OOrganon and Co
Preclinical
Aqupla
Jiangsu Simcere Pharmaceutical Co., Ltd.Preclinical
Valemetostat Tosylate
Daiichi SankyoPreclinical
Ftorafur
TThe First Affiliated Hospital with Nanjing Medical University
Preclinical
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Preclinical
Treatment
GSKPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Non-Small Cell Lung Cancer1 trial
Small Cell Lung Cancer1 trial
Tislelizumab Combined With Chemotherapy Followed by Thoracic Consolidation Radiotherapy in the First-line Treatment of Extensive Stage Small Cell Lung Cancer
Recruiting·—·Phase 2·NCT07425795·36 enrolled
Locally Advanced1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details